PARADIGM-HF
PARADIGM-HF is the largest study to date in heart failure patients. 1
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
PARADIGM-HF is the largest study to date in heart failure patients. 1
Summary:
The PARADIGM-HF study on systolic heart failure with 8,399 patients in NYHA class II-IV. 2,3...
The recently presented PIONEER-HF studies the efficacy and safety of initiating ENTRESTO compared to enalapril prior to discharge after hospitalization for an acute decompensated heart failure episode. 1 The results of PIONEER-HF...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...
Stronger Heart: In PROVE-HF, LVEF increased from 28.2% to 37.8% in patients with HFrEF treated with ENTRESTO ® at 12 months (difference, 9.4% [95% CI, 8.8% to 9.9%]; P < .001).1 Stronger Life: In...